EMEA-000084-PIP02-10
Key facts
Invented name |
Maxalt and associated names
|
Active substance |
Rizatriptan
|
Therapeutic area |
Pain
|
Decision number |
P/27/2011
|
PIP number |
EMEA-000084-PIP02-10
|
Pharmaceutical form(s) |
Tablet
|
Condition(s) / indication(s) |
Treatment of migraine
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Merck, Sharp & Dohme (Europe) Inc.
Tel. +31 412770000 |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
Compliance procedure number |
EMEA-C-000084-PIP02-10
|
Compliance opinion date |
14/09/2011
|
Compliance outcome |
positive
|